News

We are delighted to announce you that Advanced Biological Laboratories (ABL – https://www.ablsa.com) has just signed a definitive agreement to acquire CDL Pharma (http://www.cdlpharma.com/), a company headquartered in France – see the full press release. CDL Pharma Provides comprehensive biolo…

VHIR will collaborate with ABL laboratories in developing software tools

This June, the Consorcio Centro de Investigación Biomédica en Red, M.P. – CIBER, the Advanced Biological Laboratories S.A. – ABL and the Vall d’Hebron Research Institute – VHIR have signed a collaboration agreement to develop an analysis software for the high resolution subtyped results obtained on…

Advanced Biological Laboratories S.A. and Seha Connect IT Solutions LLC enter into an exclusive distribution and development collaboration agreement covering 14 countries in the Middle East region. The agreement is effective immediately and covers a large panel of clinical software developed by ABL…

Advanced Biological Laboratories (ABL) S.A. and ROCHEM BIOCARE DE PANAMA, S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Panama. See current channel partners.

Advanced Biological Laboratories (ABL) S.A. and Laborama Ltd. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Lithuania. See current channel partners.

ABL is pleased to announce the immediate available of two new DeepChek® Assays intended to be used for: Determining antiviral drug resistance to cidofovir, foscarnet sodium, ganciclovir and maribavir in patients infected with cytomegalovirus (CMV) – DEEPCHEK®-CMV UL54/UL97 ASSAY Determining dr…

ABL and Thermo Fisher Scientific Corporation are pleased to announce the execution of a supply agreement conferring to ABL the ability to combine Thermo Fisher Scientific Corporation’s Genetic Analyzers (3500 Genetic Analyzer, Applied Biosystem SeqStudio Genetic Analyzer…) with its DeepC…

ABL is pleased to announce the allowance of a new patent covering new Hepatitis B primers and kits hybridizing to DNA or mRNA of the Hepatitis B Virus Polymerase gene.

We are pleased to announce that the DeepChek®-HIV RT/PROT assay and the DeepChek®-HIV INT assay successfully passed a national and independent quality control program in France and Switzerland and obtained 100% positive results on sensibility, 100% on specificity and also 100% on scoring on HIV geno…

Together with our partner in Italy, Technogenetics, we are delighted to have two international experts in the field of molecular virology share their experience in clinical microbiology and laboratory management using our solutions (reagents and software) at the Technogenetics Satellite Symposium or…

Advanced Biological Laboratories (ABL) S.A. and ABALAT S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Mexico. See current channel partners.

We are pleased to share with you recent updates on ABL Diagnostics solutions: DeepChek Software v3.27 released including: Largescale mode: launch analyses on multiple samples simultaneously New One-page Report New version of HIVDB drug resistance guidelines (v8.4) HCV reference subtypes updated acco…

Advanced Biological Laboratories (ABL) S.A. and SafeBlood BioAnalytica S.A. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Greece. See current channel partners.

ABL is pleased to announce the immediate available of two new DeepChek® Assays intended to be used for: Determining eligibility for CCR5 antagonist treatment in patients infected with human immunodeficiency virus 1 (HIV-1) – DeepChek®-HIV V3 Loop/Tropism Assay HBV genotyping, drug resistance a…

Advanced Biological Laboratories S.A. and Right to Care enter into an exclusive distribution and development collaboration (open source) agreement covering EQUIP in 17 developing countries to strengthen HIV (and other infectious disease) treatment and prevention. Johannesburg (South Africa), Boston…